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ABSTRACT 
 
Background: In order to best treat breast cancer related lymphedema it is 
important to realize that it is a progressive, and for some, a lifelong condition 
requiring surveillance. Breast cancer patients are educated to be aware of the 
signs of lymphedema, as are physicians. This is critical to capturing those 
patients most in need of treatment since there are less options and more 
comorbidities associated with more severe swelling. Impaired shoulder usage, 
loss of range of motion and discomfort associated with the swelling of 
lymphedema can severely impact a patient’s lifestyle reducing their ability to 
work, be self sufficient and lowering their quality of life. Since 20% or more of 
patient’s treated for breast cancer will go on to deal with lymphedema in the long 
term or transiently it is necessary to understand who is most affected and at what 
level of swelling it is necessary to treat this condition.   
Methods: As a part of the lymphedema screening protocol at Massachusetts 
General Hospital we were able to analyze data on 138 women with newly 
 v 
diagnosed breast cancer. They were followed for at least 18 months and 
measured at least 3 times using the perometer, which records their arm volume 
and compares it to baseline. At the same time they were asked to fill out the 
LEFT-BC questionnaire to assess their quality of life and answer relevant 
questions relating to arm usage.  
This data was then used to analyze how each group separated by arm 
size, as either having no lymphedema, less than 10% but more than 5%, and 
those women with 10% or more relative volume change from baseline, might 
show trends in different survey responses. Six questions were analyzed at time 
points of 6, 12 and 18 months. The questions explored were: (1) I am able to 
work, (2) Because of my physical condition I have trouble meeting the needs of 
my family, (3) I feel sad, (4) I feel nervous, (5) I am losing hope in the fight 
against my illness, (6) I worry that my condition will get worse. This was then 
analyzed using a repeated measures analysis to see the trends or differences 
between these groups over time. Treatment and demographic information was 
also recorded and compared using chi-square tests to show that the groups were 
similar in composition.  
Results: The group with the highest level of swelling, 10% or more, had the 
lowest scores for quality of life and functional well-being. They were less able to 
work and meet the needs of their family and generally showed more sadness 
than the other groups. The group with low level lymphedema, 5-10% was quite 
variable and showed some trends similar to the group with the most severe 
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lymphedema but were much less affected but these women were also very 
similar to the group with no swelling for certain responses.  
Conclusions: For a condition like lymphedema there is much variability between 
patients and some women may be able to function with more swelling than 
another while others loose much of their arm function, and quality of life. The 
importance of looking at how each patient is uniquely affected will be the most 
useful tool in treating lymphedema. The study showed that arm swelling can 
possibly be a part of low functional well-being and quality of life relating to having 
lymphedema but more research needs to be done. Many researchers are looking 
for the causes of this condition but more needs to be done to see how low level 
swelling affects the patient physically, functionally, and emotionally. This would 
be beneficial to the patient, allowing them to tackle a problem before it is far 
beyond repair, and for healthcare providers to reduce costs and put resources 
where they are most needed.  
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INTRODUCTION  
 
Breast Cancer   
With as many as 226,870 women expected to be diagnosed with breast 
cancer (BC) in 2012 (SEER, 2011) it remains the most common diagnosis of 
nonskin cancer in women today (Davidson, 2007). BC, like other cancers, begins 
when a cell undergoes a mutation causing a malignant change where the cell 
cycle continues replicating unwanted cells in an unregulated fashion. According 
to Hanahan and Weinberg, there are six general traits that account for 
progression to malignant cancer (Figure 1).  
 
 
Figure 1: Acquired Capabilities of Cancer, from Hanahan and Weinberg (Cell, 
2011). Control mechanisms function normally to produce healthy cells and 
organized tissues but mutations leading to unregulated cancer growth can be 
caused by one or more of the 6 pathways. 
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Breast cancer has distinct causes that lead to loss of cell control and the 
potential to progression to cancer. As women age their risk increases, also diet 
and alcohol use can be contributing factors, exposure to estrogen, reproductive 
history such as early menarche, late menopause, having children later in life or 
not having any pregnancies. Additionally, like many cancers, environmental 
exposures have all been shown to contribute to breast cancer (Davidson, 2007).  
Specifically for BC, there seems to be two models regarding progression. 
Bombonati and Sgroi (2011) show that breast cancer may begin either 
sporadically, as a clonal growth from one cell that has undergone a mutation, or 
through cancer stem cells (cSC) where specific cells within the tumor dictate 
growth and progression. Both paths may play a role in the actual progression and 
research is ongoing to discover the specific pathways and turning points leading 
to pathogenesis. Understanding the pathways and the pathology of cancer is 
integral in treating it, as well as important in formulating targeted therapies.  
Varied causes, in combination with a variety of cancer forms diagnosed, 
ranging from large invasive tumors to ductal carcinoma in situ (DCIS), suggests 
that this disease has a very heterogeneous nature both biologically and clinically. 
DCIS is known to be a precursor to invasive cancer, but previously only account 
for 5% of cancer diagnosis (Burstein, 2004) since it previously went unnoticed 
until seen on a mammogram. This has resulted in a two-fold increase in early-
stage BC detection each year (Bleyer, 2012). Staging the disease based on 
tumor size and nodal involvement is critical in making choices regarding 
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treatment and management. Every individual’s cancer cells can differ not only on 
the presence or absence of invasive qualities, but also by the different cellular 
markers unique to the tumor. Hormone positive cancers carry either or both 
estrogen and progesterone receptors (ER and PR).  Another receptor common to 
BC tumors is the HER-2/neu receptor, which might reflect the aggressiveness of 
the tumor. This characteristic alone makes ER, PR, HER-2/neu positive cancers 
eligible for different targeted therapy approaches compared to a cancer that is 
triple negative for these receptors. The distinct features that a patient’s cancer 
can present with will influence the way the disease spreads and what tools the 
physician is able to use to treat the cancer (Davidson, 2007).  
Improved screening technology and more widespread mammography 
usage, have led to an increase in breast cancer diagnosis rates, a decrease in 
related mortality, as well as many more cases of early stage disease (Gøtzsche 
& Nielsen, 2011).  Catching any disease at an early point usually tends to have 
the best-associated outcome; this is especially true of an invasive disease like 
some forms of breast cancer. The balancing act of not over-diagnosing patients 
while being able to decrease death rates from breast cancer is a topic still much 
debated; uncertainty about cancer progression and treatment outcomes leave 
many women who have early stage disease with the decision to act radically or 
conservatively and weigh the many risks of either choice usually based on the 
fear of recurrence (Morrow, 2007).  
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Treatments  
After the initial breast cancer diagnosis is made and the staging is 
completed almost all patients will under go surgery. This ensures that the tumor 
will be removed by either a mastectomy, removal of the total breast tissue, or a 
lumpectomy, which conserves most of the breast tissue by removing only the 
tumor and a small margin of normal tissue. When the tumor is early stage there 
is the opportunity to individualize the surgical plan according to Hunt and Meric-
Bernstam (2008); since both mastectomy and lumpectomy have similar results 
the decision can be patient driven for a multitude of reasons.  
In order to make sure there are no residual tumor cells involving the 
axillary lymph nodes, the surgeon will map the sentinel nodes and determine if a 
less invasive sentinel lymph node biopsy (SLNB) can be performed. On the other 
hand, if tumor cells are extensively present within the nodes, the more thorough 
axillary lymph node dissection can be done (ALND). After surgery is confirmed to 
have removed all the cancer, then chemotherapy (CT) is begun if indicated or 
radiation therapy (XRT) dependent upon their case and pathology. Both of these 
therapies target the potential few remaining cancer cells. The majority of patients 
who chose lumpectomy will need to follow surgery with radiation to the breast, 
however, for patients treated by mastectomy, only the ones with positive axillary 
lymph nodes would need radiation to the chest wall and possible other high risk 
areas. Both groups will have less than a 10% recurrence rate after completing 
XRT (Davidson, 2007).  
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Long-term control requires hormone therapy (HT) lasting, in some cases, 
at least 5 years. Commonly this treatment consists of tamoxifen for estrogen 
receptor (ER) positive cancers or aromatase inhibitors for postmenopausal 
women only to control high levels of estrogen in the body. Herceptin, a 
monoclonal antibody drug, interacts with the HER-2/neu receptor and offers 
women with this tumor characteristic another treatment tool to create a 
personalized care plan. Additionally supportive care is offered to many patients 
ranging from peer support groups to social workers who can refer a patient for 
help coping with their disease and treatment (Davidson, 2007).  
 
Choices  
Following the diagnosis of breast cancer the patient is faced with 
numerous decisions and treatment choices that must be made in a relatively 
short amount of time. Many patients want to be a part of their decision process 
and find that this participation in their treatment planning brings higher 
satisfaction later if they are involved in the shared decision making process 
(Hillyer G.C. et al., 2012). However, it becomes difficult when, there is no 
definitively correct choice to make, a challenge that many breast cancer patients 
face. In these situations the doctors’ opinions become more important and relying 
on guidelines for clinical practice can simplify a difficult process (Katz and 
Morrow, 2012).  The American Society of Clinical Oncology (ASCO) continually 
updates oncologists about current practice guidelines or suggestions for treating 
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BC (ASCO, 2013). Some guidelines, such as the decision to omit ALND for early 
stage breast cancers when the less invasive SLNB is acceptable for disease-free 
surgery can have major implications for the patient’s survivorship and quality of 
life (QOL) (Lyman et al., 2005).  
Another aspect of the decision making process is the emerging area of 
genetic counseling. Patients can opt to have genetic testing done to learn if their 
cancer carries certain mutations known to change BC recurrence rates. If the 
patient has a family history with high incidence of cancer, especially in young 
patients, they may test for BRCA1 and 2 mutations, which are common in BC, 
and for BART which looks for large rearrangements in that gene (Shannon et al., 
2011). The benefit of this knowledge is that it is useful in planning prophylactic 
measures that can reduce the patient’s long-term risk. Kurian et al. (2012) have 
created an online tool to show patients and physicians the specific impact to 
outcomes associated with each possible option they are about to make.  
Choosing a treatment plan also involves looking specifically at the biology 
of the tumor to generate the most well tailored therapy. Patients who are ER 
positive and node negative are also able to utilize the predictive 21-gene 
recurrence score assay (OncoType Dx) to find out their sensitivity to 
chemotherapy and risk of recurrence. Unfortunately, those who receive 
intermediate score results and who are faced with making a decision to undergo 
chemotherapy or not, may have added distress leading to a decreased QOL 
(Sulayman, 2012).   
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Choosing a path for treatment requires weighing options, being well 
informed, and preparing for what is to come. Some common side effects of BC 
therapy may include the following: arm morbidities such as lymphedema, local 
pain, stiffness, weakness, neuropathy, and inflammation (Hayes, 2012). 
 
Lymphedema  
One of the most difficult complications of BC treatment is lymphedema 
(LE), which can become a life long problem beginning soon after the initial 
treatment course has ended (Hunt, Askew and Cormier, 2009). LE is caused 
when lymph, a protein rich fluid, overwhelms transportation within the lymphatic 
system in that area causing swelling as seen in Figure 2 (Cemal, 2011). For BC 
patients this is most notable commonly caused by ALND but many cases are 
complicated by other disease, treatment and patient-related causes (Van der 
Veen, 2004). Other contributors can be axillary radiation, which causes fibrosis, 
or extensive positive axillary lymph nodes, both of which will block normal lymph 
drainage and can lead to LE (Brennan, 1996; Kilbreath, 2011). 
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Figure 2: Lymphedema in two patients, from Women’s Health & Education 
Center (2011). This image depicts the size difference between a normal and 
affected arm.  
 
 
Many clinicians and researchers are still struggling to determine why some 
women will develop breast cancer related lymphedema (BCRL) and others with 
matched treatment plans will not and further research is ongoing (Paskett, 2012). 
Furthermore, the incidence of LE is so poorly documented that it is unclear how 
many women are affected at all. A Meta analysis by Erickson (2011) of 10 
previous LE studies reported various rates from 0% to 56% after two years. The 
consensus seems to suggest an incidence somewhere between 20-30%. 
 Beyond inconsistencies in overall reported incidences there still remains 
much variation in methods for detecting LE.  Widely used methods, include 
circumferential tape measurement and water displacement (Figure 3); both 
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methods are able to distinguish the presence of LE but lack consistency and 
repeatability (Taylor, 2006; Hunt, Askew and Cormier, 2009). Furthermore, the 
range of confirmed LE depends on clinical cutoffs that seem somewhat arbitrary; 
many women with even low or no clinical lymphedema who are experiencing 
symptoms may disagree with a 10% volume change from baseline as being the 
definition of lymphedema. Armer et al. found that a 10% volume change from 
baseline was a conservative cutoff point and may not include all cases of self-
reported or clinically relevant LE (Armer and Stewart, 2005; Paskett, 2012). 
BCRL may also be difficult to detect using this method since some patients 
initially have arms of different sizes and it is difficult to limit all sizes of women to 
the basic diagnostic tools such as 2 cm differences. To be able to effectively 
diagnose and treat these patients’ LE, there needs to be a way to identify LE as it 
progresses, and not only as it hits a peak value, since it is not a static condition 
(Ancukiewicz et al., 2012). Utilizing prospective screening allows for longitudinal 
data to be collected from their preoperative state through recovery, which can 
show temporal changes.  
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Figure 3: Using water displacement measurement, from Johansson, 2010. 
Water displacement is one technique used for measuring BCRL in some clinics. 
 
One way to meet this need is to use electro-optical perometry to visualize 
arm volume changes (Ward, 2009). In a large-scale study of practice guidelines 
perometry is recommended as a more suitable measurement tool as compared 
to circumference methods (Harris, 2012). The Perometer is used to measure arm 
volumes and finds percent difference between the contralateral and ipsilateral 
arms. The accurate and reliable arm volume measures obtained via perometry 
are best qualified using the relative volume change (RVC) equation: RVC = 
(A2U1)/(U2A1) − 1, where A1, A2 are volumes on the side of the treatment at two 
different time points, and U1, U2 are volumes on the opposite side (Figure 4) 
(Ancukiewicz et al., 2011). This formula accounts for any normal asymmetry 
between the arms, utilizes the unaffected arm as a control, and allows for the 
168 K. Johansson & E. Branje
after the 10-years follow-up period. Relevant data 
was collected from the patient’s record (Table I). 
 In the control group 2 patients with lymphoe-
dema that had not been included in the oedema 
group were indentifi ed. One had been lost to follow-
up, the other had developed lymphoedema during 
the last month before the fi nal measurement. These 
two patients were not included in the oedema group 
for analysis. Thus the negative predictive value for the 
control group was 95%. 
 Measurements 
 Arm volume.  Arm volume was measured with the 
water displacement method (Archimedes principle) 
which is used as the gold standard of limb volume 
measurements [14]. The method has been described 
by Kettle [15] who found a standard deviation of 
1.5% from the mean volume of repeated measure-
ments. Bednarczyk et al. [16] carried out a validity test 
for the water displacement method with a comput-
erised limb volume measurement system (CLEMS). 
Eighteen legs were measured with both methods 
showing mean volume 3177 ! 844 ml determined by 
water displacement method and 3164 ! 789 ml by 
CLEMS with no signifi cant difference and a high cor-
relation coeffi cient ( r  " 0.992). Further, they mea-
sured plaster fi gures and demonstrated that CLEMS 
had a high test-retest correlation ( r  " 0.999). 
 In the Lymphoedema Unit, a cylindrical con-
tainer with a soft drain pipe 45 cm above bottom 
was fi lled with water. Each arm was submerged in 
a straight position with the fi st resting with the 
proximal phalanges at the bottom (Figure 1). The 
displaced water was collected in a tank and weighed 
in grams with a precision of 1 g and translated into 
millilitre (assuming water has a density of 1 g/ml). 
The contralateral arm was used as control at each 
occasion.  
 The lymphoedema absolute volume (LAV) was 
obtained by calculating the difference in volume 
between the arm on the treated side and the contral-
ateral arm. The lymphoedema relative volume (LRV) 
was calculated using the following formula: 
 Vol. arm treated side  – vol. contralateral arm × 100 
 vol. contralateral arm 
 By using this formula, differences in build and 
body shape is taken into account. The use of the 
contralateral arm acts as a control and the relative 
volume increase can be calculated. Two people with 
the same LAV will have different LRV depending on 
if they are overweight, with a fat untreated arm, or if 
the untreated arm is slender.  
Table I. Characteristics, lymphoedema group (n"98) at time of 
arm lymphoedema diagnosis and controls (n"40) at end of the 
study.
Oedema group Controls
n"98 n"40
mean!SD 
(median)
mean!SD 
(median)
Age, years 63.4 ! 11.3 (57.0) 58.9 ! 11.4 (60)
Op site, right/left 57/41 21/19
Op side, dominant/
non dominant
60/38 20/20
Time from op to 
oedema diagnosis, 
months
11.5 ! 12.8 (9.0)
Time from op to last 
measurement, 
months
43.0 ! 32.5 (31.0) 72.6 ! 30.0 (54.5)
BMI∗ 25.8 ! 4.1 (25.9) 25.9 ! 4.5 (24.7)
Arm volume op, ml 2468 ! 420 (2440) 2375 ! 514 (2270)
Arm volume 
contralateral, ml
2284 ! 391 (2269) 2344 ! 504 (2294)
LAV∗, ml 183.5 ! 79.1 (166) 30 ! 92 (22)
LRV∗, % 8.1 ! 3.6 (7.0) 1.4 ! 4.3 (1.1)
∗BMI: Body Mass Index, LAV: Lymphoedema absolute volume, 
LRV: Lymphoedema relative volume
Table II. Defi nition of the sub groups with breast cancer related 
arm lymphoedema.
Early BCRL was defi ned as arm lymphoedema diagnosed # 
12 months after operation. Patients with early BCRL had all 
been diagnosed within the routine follow-up. 
Late BCRL was defi ned as arm lymphoedema diagnosed $12 
months after operation. Patients with late BCRL had either 
contacted the Lymphoedema Unit themselves or been referred 
by a physician. 
Small LRV was defi ned as LRV 5–%10.0% at time of diagnosis.
Large LRV was defi ned as LRV&10.0% at time of diagnosis.
Regular treatment was defi ned as treatment at least twice a 
year with at least two compression sleeves. 
Non-regular treatment was defi ned as treatment frequency less 
than twice a year or with longer intervals by the patient’s choice.
 
Figure 1. Measurement of arm volume with water displacement 
method. 
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quantification of relative arm volume changes over time, from baseline through 
postoperative treatment.  
 
 
Figure 4: Depiction of the Perometer in use at the MGH, from Ancukiewicz et 
al. (International Journal of Radiation Oncology Biology Physics, 2011). The 
suggested arm placement for use of the Perometer is shown to ensure accurate 
and repeatable methods. 
 
 In some cases, LE has been shown to be a transient condition. Lack of 
evidence makes it difficult to determine if the patient will ultimately be affected in 
the long-term as rates of development are widely unknown. Wondering if they 
may need clinical management, such using a compression sleeve or physical 
therapy, or if the condition will resolve on its own are some of the questions 
patients are left facing. Hayes et al. (2008) found that up to 60% of cases were 
 12 
managed without treatment and resolved within 3 months while the rest went on 
to be long term and chronic LE. This means that women not only face the 
struggles of coping with their initial BC treatment, but that soon afterwards, they 
must face the reality of their potential risk for developing LE, as most self 
reported cases of lymphedema are known to occur in the first year after 
treatment (Gärtner, 2010). The unknown aspect of how long the problem will last, 
if it will require further physical therapy, and if a compression sleeve must be 
worn at all times adds to the uncertainty and fear associated with LE.  
 
Functional Well-Being and Quality of Life 
 LE and other post-treatment complications cause long-term consequences 
on survivors’ function and QOL. Overall, the presence of BCRL can be a 
continual source of anxiety and worry for women as it persists and reminds her of 
the earlier cancer fears. It can make functioning normally difficult and requires 
understanding of the emotional issues as well as the physical problems that may 
include treatment or physical therapy (Maguire, 1999).  
Recently, due to awareness, more patients are identifying LE as it affects 
their function and is noticeable to them but remains below the threshold of 10% 
volume change. This encourages the idea that self-reporting functional problems 
may be an accurate and important part of diagnosing and treating the many 
women dealing with low level BCRL (Pain, 2003).  
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According to Dorval et al, it was shown that women treated for BC, 
compared to matched controls, were more likely to have arm morbidities and 
self-reported lower QOL for some time (Dorval, 1998). Arm morbidities including 
tightness, swelling, numbness and pain can affect both function and obviously 
also influence QOL as any hindrance to using one’s arm means a decrease from 
full potential. Even after many years, women who undergo ALND are more likely 
to have these limitations to function. When looking longitudinally at this data, 
Land et al. found that some of these arm problems seem to dissipate in some 
women while others continue to experience them after one year and onward 
(Land, 2010).  
 Functional well-being (FWB) is a problem for many women treated for BC 
with nearly one quarter of women attesting to it affecting their work and regular 
activities. For those with severe functional impairment, it has been shown to be 
as high as nearly 50% (Kopec, 2012). Stamatakos et al. (2011) reviewed much of 
the BCRL literature and found that it is common for women to experience pain, 
swelling, and heaviness in the affected limb, among other issues that restricts 
them from working and also accomplishing household chores. Additionally, 
patients face body image issues, anxiety and depression, which add to their 
psychosocial distress; some even require psychiatric services to address these 
issues. 
 
 
 14 
Implications for Survivorship 
 With more women affected each year, and improved clinical management 
for the disease, there is now an ever growing population of BC survivors. As of 
2009, it was estimated that there are 2,747459 women living with a history of 
breast cancer (SEER, 2012). Being a cancer survivor, according to the National 
Cancer Institute, begins at diagnosis and continues on for the entirety of the 
patient’s life (NCI, 2013). These women face many challenges long after their 
diagnosis and immediate treatment. BC is known to be a slow growing disease 
and therefore the waiting game can be a powerful part of a survivor’s life; waiting 
to see if there will be a recurrence can be as much of a struggle as dealing with 
the complications after treatment has ended (Waldrop, 2011).  
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SPECIFIC AIMS 
 
In this paper, the importance of breast cancer survivors’ long-term 
functional well-being and present and future QOL as related to LE development 
will be explored. The goal of the current study is to determine how differing levels 
of LE affect functional well-being and QOL over the course of 18 months after 
initial treatment. Those with higher level LE are expected to be the most severely 
affected as is generally found to be true compared to controls. This study will 
also seek to evaluate how women with lower level LE are affected compared to 
women without LE.  
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METHODS 
 
Study Design 
 This observational study followed the protocol set forth under the clinical 
trial “Prospective Analysis of Symptoms and Lymphedema in Patients Following 
Treatment for Breast Cancer” at the Massachusetts General Hospital (MGH), 
Boston (Clinicaltrials.gov: NCT01521741). The objective of this study is to 
investigate the patient's long-term functional well-being and QOL changes 
relating to LE in a cohort of BC patients.   
The Perometer was used to measure patients’ arm volumes according to 
the methods outlined in the protocol. This allowed for a preoperative baseline 
measurement, and after surgery, CT and XRT and then follow up measurements 
every 3-8 months. In conjunction with each perometer measurement, patients 
completed a questionnaire regarding symptoms, function and QOL. This 
questionnaire is a condensed form of the combined Lymphedema and Breast 
Cancer Questionnaire (LBCQ), the Disabilities of the Arm, Shoulder and Hand 
(DASH), and the Functional Assessment of Cancer Therapy- Breast (FACT-B) 
validated surveys; it is referred to as the Lymphedema Evaluation Following 
Treatment for Breast Cancer (LEFT-BC). The LEFT-BC survey was administered 
each time the patient came in for a perometer measurement and was either to be 
completed during the visit using a tablet which uploads the data directly to a 
database, or later mailed in as a paper copy.  
 17 
Participants 
 The study was open to all newly diagnosed patients who received a 
baseline arm volume measurement by perometry, and completed the LEFT-BC 
questionnaire, at baseline, prior to surgery. The eligibility criteria for inclusion in 
this study were: (i) must have newly diagnosed BC which is pathologically 
confirmed as cancer or carcinoma in situ, (ii) must be without previous history of 
breast cancer OR lymphedema, (iii) the patient must be a female, age 18 years 
or older, and (iv) must be without known metastatic disease and no prior surgery 
or radiation to the head, neck, or upper thoracic region, (v) must have a baseline 
measurement, (v) must have at least 18 months of follow-up.  Additionally, since 
the measurements are taken at the Gillette Center for Breast Cancer at the MGH 
any patient who was not able to return for treatment and follow-up at MGH was 
excluded from the study. All patients treated at MGH for BC who meet the trial 
criteria were eligible, and those who chose to enter were enrolled in the study to 
be screened using both the perometer and the LEFT-BC survey. 
In order to properly investigate FWB long-term it was decided that patients 
must have over one year of measurements in order to look beyond initial 
treatment related complications which are usually completed by 6 months after 
diagnosis (Hayes et al., 2008). Thus, participants were required to have at least 
18 months of follow-up after their initial breast cancer diagnosis. This criterion 
yielded a cohort of 138 patients (N=138). Eighteen months was deemed suitable 
since many women have LE within their first year post treatment, and by 18 
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months 30% have developed symptoms so the majority of cases would be 
captured in this cohort (Hayes et al., 2008). 
 
Data Collection and Process 
The patients’ survey data was either retrieved from the tablet database or 
from the paper survey database. Their answers to certain questions pertaining to 
FWB and QOL were then combined in Excel. The questions used to assess FWB 
were: (1) I am able to work, (2) Because of my physical condition I have trouble 
meeting the needs of my family, (3) I feel sad, (4) I feel nervous, (5) I am losing 
hope in the fight against my illness, (6) I worry that my condition will get worse. 
 Relevant information about the patient’s treatment for BC was also 
included in the analysis in order to investigate the impact of specific treatments 
for breast cancer on their long-term FWB. Table 1 displays the treatment-related 
information included in the analysis. This information was obtained from the 
Partner’s Health Care Longitudinal Medical Record system (LMR). Information 
regarding patient demographics was also found in the same manner and this 
included the following: age at diagnosis, handedness, marital status, number of 
children, and employment type (Table 1).  
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Table 1: Therapy-Related Information  
 
Treatment/Category  Specific information included 
Cancer Type: in situ or invasive  
Pathologic stage  
Grade 
Surgery * Type: lumpectomy or mastectomy 
Nodal sx: SLNB or ALND 
Number of nodes removed  
Number of positive nodes 
Chemotherapy * Type: neoadjuvant before or adjuvant 
after sx 
Regime and dosing 
Number of cycles 
Duration of treatment  
Radiation * Dose 
Fields, area of directed treatment 
Fractions 
Energy level 
*(Surgery, chemotherapy, and radiation also include no treatment as an option) 
 
 Information regarding patient demographics was also found in the same 
manner and this included: age, age at diagnosis, handedness, marital status, 
children, and employment.  
 
Data Analysis  
The cohort of N=138 patients was then separated by their LE status using 
the RVC value generated using the perometer data. Those patients who 
experienced an RVC of 10% and above were separated into group 1 (N=10), 
those with an RVC at any time in the recorded 18 months of 5% up to 10% were 
group 2 (N=35), and those with no previous events of an RVC above 5% were 
group 3 (N=93). This allowed for three groups to be compared so that differences 
 20 
between those with no lymphedema and those at differing levels of LE could be 
discerned.  
 The LEFT-BC survey allows for patients to chose from five possible 
choices: (0) Not at all, (1) A little bit, (2) Somewhat, (3) Quite a bit, (4) Very much 
and for those who marked that they did not want to answer a question, or if the 
result was left blank, it was scored as unknown (U) The survey is easily filled out 
by hand or using a tablet device and responses are marked as seen in Figure 5. 
 Not at 
all 
A 
little 
bit 
Somewhat Quite 
a bit 
Very 
much 
Do not 
wish to 
answer 
I am able to work     ✔  
Because of my 
physical condition, I 
have trouble meeting 
the needs of my family  
 ✔     
I feel sad   ✔    
I feel nervous   ✔    
I am losing hope in the 
fight against my illness 
✔      
I worry that my 
condition will get 
worse  
  ✔    
Figure 5: Example of Responses in the LEFT-BC Questionnaire: This shows 
the questions patients complete in the LEFT-BC survey and an example of how it 
would be marked by the patient. 
 
A repeated measures model was chosen to compare between groups and 
within each group over time points of 6, 12 and 18 months. For each question 
used from the survey a separate analysis was done to see what specifically was 
contributing, if any, to a change in self-reported FWB and QOL relating to their 
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having LE or not. The data was analyzed using SPSS version 20 with the 
variables set as scale variables; output tables and graphs were generated using 
this program as well (IBM SPSS 20, 2013). 
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RESULTS 
 
Qualitative Results  
 Aspects regarding patient demographics were looked at to explore 
similarities or differences between groups; these are shown in Tables 2 and 3.  
Table 2: Treatment-related information: Surgery and other treatment variables 
are shown for the whole cohort and for each subgroup 
 
Treatment information Group 1 
N=10 
Group 2 
N=35 
Group 3 
N=93 
Average 
N=138  
Median age at dx- 
       Range- (36-79) 
55 57.9 55.3 55.97 
Surgery type- 
       Lumpectomy 
       Mastectomy 
 
7 (70%) 
3 (30%) 
 
27 (77.1%) 
8 (22.9%) 
 
68 (73.1%) 
25 (26.9%) 
 
102 (74%) 
36 (26%) 
Tumor type- 
       DCIS 
       Invasive 
 
0 
10 (100%) 
 
3 (8.6%) 
32 (91.4%) 
 
8 (8.6%) 
85 (91.4%) 
 
11 (8%) 
127 (92%) 
Type of node surgery- 
       None 
       SLNB 
       ALND 
 
0 
2 (20%) 
8 (80%) 
 
1 (2.9%) 
27 (77.1%) 
7 (20%) 
 
5 (5.4%) 
67 (72%) 
21 (22.6%) 
 
6 (4.3%) 
96 (69.5%) 
36 (26.2%) 
Number nodes removed- 
      None 
      Less than 5 
      5 or more  
 
0 
2 (20%) 
8 (80%) 
 
1 (2.9%) 
25 (71.4%) 
9 (25.7%) 
 
5 (5.4%) 
62 (66.7%) 
26 (27.9%) 
 
6 (4.3%) 
89 (64.5%) 
43 (31.2%) 
Neoadjuvant CT- 0 2 (5.7%) 3 (3.2%) 5 (3.6%) 
Adjuvant CT- 6 (60%) 13 (37.1%) 36 (38.7%) 55 (39.8%) 
Radiotherapy- 9 (90%) 31 (88.6%) 72 (77.4%) 112 (81%)  
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Table 3: Demographics information: Marital status, children and work 
environment percentages are included for the whole cohort and for each 
subgroup 
 
Demographics Group 1 
N=10 
Group 2 
N=35 
Group 3 
N=93* 
Average 
N=138  
Marital status 
     Married/partner 
     Divorced 
     Single 
     Widowed  
 
8 (80%) 
0 
1 (10%) 
1 (10%) 
 
24 (68.6%) 
2 (5.7%) 
5 (14.3%) 
4 (11.4%) 
 
69 (74.3%) 
13 (13.9%) 
6 (6.4%) 
5 (5.4%) 
 
101 (73.2%) 
15 (10.9%) 
12 (8.7%) 
10 (7.2%) 
Children 
     None 
     1-2 
     3 or more  
 
3 (30%) 
6 (60%) 
1 (10%) 
 
9 (25.7%) 
17 (48.6%) 
9 (25.7%) 
 
16 (18%) 
43 (48.3%) 
30 (33.7%) 
 
31 (22.4%) 
66 (47.9%) 
40 (29.6%) 
Work environment 
     Active        
     Home 
    
 
3 (30%) 
4 (40%) 
 
8 (22.9%) 
12 (34.3%) 
 
22 (23.7%) 
35 (37.6%) 
 
33 (23.9%) 
51 (37%) 
 
*For group 3: 4 patients have no accurate data regarding children so N=89. 
 
Even with uneven group size, all share very similar compositions; the 
exception being group 1 which is so small it may not be close to the average for 
certain criteria which are correlated to their having BCRL such as nodal surgery.  
One specific difference within type of nodal surgery shows that participants in 
group 1 underwent far more ALND than SLNB, whereas participants in groups 2 
and 3 underwent predominantly more SLNB.  Group 1 also received more 
chemotherapy than the other groups possibly since none of those cases were 
DCIS, while groups 2 and 3 had 8.6% DCIS.  
Patient demographics were also very comparable overall. Additionally, 
work environment characteristics were also very similar meaning that 
comparisons between groups relating to this and FWB will accurately show 
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differences without interactions of these confounding the results. When a chi-
square test was done to test for a difference between the three groups regarding 
work environment (X2 = 1.600, df =2) there was no significance. Similarly for 
working at home (X2 = 0.449, df =2) there was no difference across groups.  
 
Functional Well-Being  
The three groups, separated by different LE status, all show similar trends 
for the questions on the LEFT-BC survey regarding FWB and work such as; (Q1) 
I am able to work, and (Q2) Because of my physical condition I have trouble 
meeting the needs of my family. All three groups over time showed an 
improvement in their self reported feelings about their ability to work, as time is 
the only significant variable with a p-value < 0.0001 (Table 4). Those with more 
significant LE (≥10%) had lower mean scores at each time point compared to the 
other groups. The opposite trend is shown between group 2 and 3 there is the 
opposite trend seen. For question 1, higher scores show a greater ability to work 
and for question 2 lower scores show that their FWB was less affected; this 
difference is based on the wording of the questions.  
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Table 4: Mean Scores for Questions 1 and 2: (1) I am able to work and (2) 
Because of my physical condition I have trouble meeting the needs of my 
family 
Group Mos Q1 Mean Q2 Mean 
1 
 
 
6 
12 
18 
2.800 
3.600 
3.500 
.900 
.400 
.500 
2 6 
12 
18 
3.364 
3.697 
3.697 
.471 
.176 
.147 
3 6 
12 
18 
3.299 
3.609 
3.552 
.345 
.250 
.155 
 
The within subjects repeated measures results for question 1 shows that 
the interaction of time is significant (p-value < 0.0001, F= 12.912) but for the 
interaction of time by groups it is not significant (p= 0.409, F=0.998) when 
sphericity of the data is assumed, which it can be by SPSS with significance of p 
< 0.0001 (Figure 6). 
Within subjects for question 2 the interaction of time is significant (p-value 
< 0.0001, F= 9.184) but for the interaction of time by groups it is not significant 
(p= 0.286, F= 1.260) (Figure 7). 
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Figure 6: Change in “I am able to work” responses over time: (Group 1: ≥ 
10%, Group 2: 5% to 10%, and Group 3: less than 5%) those with the most 
significant LE in group 1, had the lowest initial scores regarding their ability to 
work, while the other two groups showed similar trends over time but with group 
2 having the best responses.  
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Figure 7: Change in “Because of my physical condition I have trouble 
meeting the needs of my family” responses over time: This graph shows that 
those with 10% LE in group 1 seemed to be most affected when it comes to 
meeting the needs of their families while groups 2 and 3 have overall lower mean 
scores that those patients in group 1. 
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Present Emotions 
To assess QOL at each time point the questions (Q3) I feel sad, and (Q4) 
I feel nervous were included in separate analyses with values shown in Table 5.         
 
Table 5: Mean Scores for Questions 3 and 4: (3) I feel sad, and (4) I 
feel nervous 
Group Mos Q3 Mean  Q4 Mean 
1 
 
 
6 
12 
18 
1.111 
1.111 
1.333 
.889 
1.000 
1.111 
2 6 
12 
18 
.571 
.514 
.486 
.743 
.629 
.514 
3 6 
12 
18 
.977 
.828 
.770 
1.227 
1.011 
1.000 
 
Emotional well-being and QOL scores for all groups were low, showing 
none of the groups had significant negative responses during the 18 months 
following treatment. As some groups decreased their level of sadness and other 
increased it shows time is not a contributing factor (p= 0.774, F= 0.256).  There 
was no interaction between groups seen for either Question 3 (p= 0.543, F= 
0.775) or Question 4 (p= 0.512, F= 0.822) (Figure 8). 
The same trends were seen in responses to Question 4 over time and 
also showed that time was not significant (p= 0.702, F= 0.354).  Group 2 had the 
overall lowest scores and both group 2 and 3 showed improvement over time 
while group 1 reported higher scores for sadness and nervousness (Figure 9).  
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Figure 8: Changes in “sadness” over time: From the plot for question 3, group 
2 had the overall lowest scores; they decreased over time showing less sadness 
as time went on. Those in group 3 also showed less sadness overtime. Group 1 
responded in an opposite trend showing more sadness over time, and were the 
highest scorers showing an overall higher level of sadness than the other two 
groups.  
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Figure 9: Changes in “nervousness” over time: Group 2 had the lowest 
scores overall and experienced a decrease in nervousness overtime. The women 
in group 3 had the highest scores initially but decreased longitudinally. As time 
went on, those in group one gradually increased their level of nervousness and 
ended at 18 months with the highest scores of the three groups.  
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Future Fears 
 The questions that address future fears and QOL were: (Q5) I am losing 
hope in the fight against my illness and (Q6) I worry that my condition will get 
worse (Table 6). 
Table 6: Mean Scores for Questions 5 and 6: (5) I am losing hope in the 
fight against my illness, and (6) I worry that my condition will get worse 
Group Mos Q5 Mean  Q6 Mean 
1 
 
 
6 
12 
18 
.111 
.111 
.111 
1.300 
1.100 
1.200 
2 6 
12 
18 
.000 
.114 
.114 
.909 
1.152 
1.182 
3 6 
12 
18 
.045 
.034 
.023 
1.128 
1.023 
.977 
 
 For question 5 there is no significance for time (p = 0.685) or between 
groups (p = 0.265). All three groups had similar, low level scores close to 0, 
representing little to no loss of hope in their fight (Figure 10). 
The results for question 6 shows that group 1 had the highest overall 
scores at all time points. Within subjects analysis for question 6, showed that 
time is not significant (p = 0.954, F= 0.047) and for the interaction of time across 
groups is also not significant (p= 0.061, F= 2.283) for this question (Figure 11).  
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Figure 10: Change in “I am losing hope in the fight against my illness” 
responses over time: The most affected and the least affected groups are 
separated the most showing a difference in responses. More women in group 3 
showed more hope, and had overall lower scores, and this decreased over time. 
The group 1 women had slightly higher scores showing an increase in responses 
of losing hope in the fight against their disease, and this remained constant 
during the whole duration. This is not seen in group 2, however. These women 
jump from the lowest scores to the highest within the first year and remain higher 
than even those in group 1.  
mos
321
E
st
im
at
ed
 M
ar
gi
na
l M
ea
ns
.12
.10
.08
.06
.04
.02
.00
Estimated Marginal Means of MEASURE_1
3
2
1
Group
Page 7
 33 
 
6                12         18 
           Months 
 
Figure 11: Changes in “I worry that my condition will get worse” responses 
over time: Across all three groups there are other aspects affecting their 
answers as no trends are really seen regarding their level of worry over time. 
Group 1 has an initial decrease and then a gradual recurrence of worry at 18 
months. Group 2 women show increased worry about their condition over time 
while group 3 shows a decreasing trend towards worry at one year and 18 
months after baseline. Again, group 2 begins with the lowest scores but 
drastically increases to the highest score at one year above both other groups.  
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DISCUSSION 
 
Functional Well-Being 
 As expected those women with 10% RVC showed overall more of an 
effect of their condition resulting in limitations in ability to work and difficulty 
meeting the needs of their families. Having LE, therefore, may impact FWB 
especially for those with significant swelling although further investigation is 
needed. 
 Both groups with LE show significant improvements in FWB from the 
beginning of their treatment to the first 12 months, but show much less of an 
increase out to the 18 month data point. This is not seen in the group without LE 
possibly since they are steadily improving over time due to the usual time course 
for recovery from BC therapy and treatment. Possibly the patients with LE see 
less improvement from 1 year to 18 months out due to the lingering 
complications of their LE which can affect their FWB even once regular healing 
and adjuvant treatments have ended. Those women experiencing some effects 
of LE and the lingering fear and distress that accompany the condition (Waldrop, 
2011) may feel less able to work and believe that they are still affected in 
meeting the needs of their families due to their BCRL.   
The inconsistent trends seen in groups 2 and 3 might suggest that other 
factors are at play. The effects of specific surgeries and treatments may have 
been confounding variables especially in questions regarding their ability to work 
 35 
and FWB. Many women experience fatigue, loss of energy (Rosedale, 2010) and 
cardiac toxicity (Khouri, 2012) after breast cancer treatment especially due to 
chemotherapy use. Over time the changes seen may have been caused by this 
interaction as well as due to the LE. According to Ganz et al. (2011) it is known 
that QOL usually does significantly improve in the year following breast cancer 
treatment, regardless of the type or severity of the treatment. Those with more 
severe and persistent symptoms tend to be those who did receive chemotherapy. 
Conversely, according to a review of the literature by Lee et al. (2008) it was 
concluded that radiation was not a precipitator of arm problems although it did 
cause some problems with shoulder function, and it also was not a cause for 
lowered QOL. 
Taking this into account, it seems that the low level LE group and the 
group unaffected by LE show similar results for reasons relating to their initial 
treatment, radiation, and chemotherapy as well as their LE status. It would be 
good to see where these patients chart later on, if their LE resolves and how 
these things affect their condition and FWB. 
 
Present Emotions 
 Over time, those with low levels of LE and no LE have less sadness and 
nervousness over time. Women in group 1, however, have more of both of these 
negative emotions over time. It is possible that their long lasting condition 
negatively impacts their day-to-day QOL by causing them more distress and 
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sadness than other groups. Those women with low level LE had the lowest 
scores of all groups for both sadness and nervousness. This may have been due 
to the fact that it was a small group, whereas, group 3 is much larger and any 
outliers may have more of an effect. It is important to note that on average none 
of the three groups had more than an average of “somewhat” sadness or 
nervousness.  
 Emotions can vary so much over time and since these data points are just 
one-day snapshots, therefore, they do not represent all of these likely changes 
over time. Also sadness and nervousness are impermanent emotions not only 
related to only LE but a range of other stressors both health-related and 
personal. Up to one-third of BC patients are so affected by their condition that it 
leads to depression, anxiety disorders, or adjustment problems (Maguire, 1999).  
 
Future Fears 
 The question, “I am losing hope in the fight against my illness” had the 
lowest overall scores among groups of all the questions analyzed. Initially, it was 
not thought that this would be so polarizing. The community here at MGH is a 
critical part of their confidence since compassionate care and positivity can bring 
a lot of calm to worried patients. The strong community of all BC survivors also 
plays a role in their refusal to quit or lose hope. According to Documet et al. 
(2012), women with BC defined survivorship not only as being in a cancer free 
state after treatment, but as a part of their outlook on life. They believed in 
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helping others on their journey through cancer, being a source of strength for 
others, and helping find positivity in setbacks and adversity. For all of the groups, 
the low scores reflected this positivity in outlooks. Group 2 was the only group to 
have a higher perceived loss of hope, but since it was a small sample it may also 
be due to by small sample size. However, it may also show some correlation 
between developing LE and an impact on future fears. Group 1 had slightly 
higher scores than the other groups and remained unchanged overtime 
suggesting that their BCRL may be tied to this loss of hope.  
 Fear of the future, of recurrence, and fears for one’s family are found to be 
issues that affect all women with breast cancer (Waldrop, 2011). This was seen 
slightly in this cohort as well, although overall the scores were low but still 
correlated with time. As the recovery process reached into the second year both 
groups affected with LE had significant jumps in worrying if their condition would 
get worse. This later time trend is not seen for group 3 as they become less and 
less worried over time as their treatments end and recovery stabilizes. The 
lymphedema patients are not following this trend possibly due to the daily 
reminder of LE. Group 2 with the low level of LE showed even worse scores than 
those with 10% RVC at one year. This dramatic difference may show the impact 
of developing LE, at any level, has on worry.  
 Many breast cancer survivors experience higher distress, and lower QOL 
during their treatment and for years to come. This implication carries over to the 
family members and can create additional concerns for the patient about their 
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and their family’s future (Waldrop, 2011).  The cycle of worry leads many patients 
to withhold these concerns from their physicians while they confirm their poor 
outlook themselves, thus reinforcing this negative psychological coping (Maguire, 
1999).  
 
Limitations  
 From our data it is clear that the LEFT-BC survey as a whole is quite 
helpful in assessing the patient’s QOL relating to lymphedema at that point in 
time. However, each question separately only targets a specific emotion or 
aspect of life. Therefore the answers may be related to how they feel that day 
regardless of their condition in the month before, and if their condition is affecting 
their mood or function that day. What is seen may also be just a snapshot rather 
than the actual complexities of the condition over time, so more frequent data 
points could be used for those patients during an episode of LE or those already 
with clinical BCRL.  
 Macefield et al. (2013) found that patient-reported outcomes in arm 
morbidity may be more valuable than clinical cancer outcomes since they are 
able to show how different aspects of treatment affect arm morbidity and QOL in 
the short term. This means that the data gathered here can reflect how these 
women’s recoveries changed overtime and developed into a life of survivorship 
where improvement in all aspects of FWB and QOL is the main goal. 
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 Selection bias accounts for some of the limitation of this study.  All 
baseline new breast cancer patients are approached to be involved in the 
screening but some are unable to return to the MGH, may chose to not come to 
the perometer room to be measured, or fail to return their questionnaires. 
Additionally, those with ALND and more severe cases may be a higher 
proportion of patients screened since they are more at risk for developing LE, 
thus more closely followed and willing to participate more frequently.  
 
Future Studies  
Lymphedema diagnosis and management needs to become more uniform 
to better serve the patient and the healthcare field overall. Hayes et al. 
recommend that immediate prospective surveillance of patients may be 
beneficial since it notifies the patient while they are in the hospital setting and can 
still receive treatment, and it may help target minorities and women in lower 
socioeconomic groups. They also showed that it is feasible in a breast clinic 
setting already (Hayes, 2012). 
From a healthcare perspective, lymphedema causes a serious increase in 
post-treatment spending according to Shih et al. who found an additional 2 years 
cost of BCRL ranging between $14,00-$23,000 for all related medical expenses 
(Shih, 2009). Screening may be a tool to decrease this as early detection leads 
to a substantial decrease in cost from over $3,000 to treat one individual to only 
$600 (Stout, 2012). This is one area where a complication of BC treatment that is 
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well understood by both patient and physician can be managed and not only left 
to chance. While developing BCRL is still uncertain in each patient this begins to 
bring some management to a confusing and complicated world for breast cancer 
survivors. 
Exercise after breast cancer treatment may be another way to help 
improve function without causing arm morbidity or being harmful to QOL as seen 
in the RESTORE trial (Anderson, 2012). This may present a way to improve 
patients health and decrease LE problems all with less healthcare spending. 
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CONCLUSION 
 
In conclusion, the impact of developing LE, at any level, on a woman 
recovering from breast cancer cannot be overlooked as it affects more that 20% 
of all patients. It affects their functional well-being, their emotional well-being, 
their QOL and fears for the future. Lymphedema education has enabled women 
to understand the changes associated with the progression of the condition so 
that they can become an active part of their treatment. Self reported LE could be 
found as a slight volume change and should be evaluated and managed. The 
patients seen here with 10% or more RVC are usually the most severely affected 
when it comes to function and QOL, but it is important to not forget that those 
with lower levels of LE, whether measured using perometry, measuring tape, or 
by self report may also be personally affected even if not clinically classified as 
having LE. Diagnosing a condition that progresses and changes over time 
requires the ability to accommodate the need when it is found. Those requiring 
treatment and management at all levels deserve attention; the emphasis on 
returning all patients back to full function and restoring a high QOL should remain 
the goal overall regardless of numbers.  
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